Abstract 20P
Background
In this analysis, we examined the efficacy, feasibility and limitations of the application of mTOR inhibitors based on the individual molecular profile of heavily pretreated cancer patients after failure of all standard treatments.
Methods
In this single-center, real-world retrospective analysis of our platform for precision medicine, we analyzed the molecular characteristics of 70 cancer patients. Tumor samples of the patients were analyzed using next-generation sequencing panels of mutation hotspots, MSI testing, and immunohistochemistry. All profiles were reviewed by a multidisciplinary team to provide a targeted treatment recommendation after consensus discussion.
Results
Seventy cancer patients with activation of the p-mTOR pathway were offered a mTOR inhibitor-based targeted therapy and 17 (24%) of them eventually received the targeted therapy. Four patients (6%) achieved stable disease. The other 13 patients (19%) experienced progressive disease. The median time to treatment failure was 3.2 months. In total, we detected 133 mutations in 60 patients. The five most frequent mutations were TP53, PTEN, KRAS, ATR, and POLE that accounted for over 40% (46%) of all mutations.
Conclusions
The antitumoral activity of mTOR inhibitor in therapy-refractory solid tumors was modest.
Legal entity responsible for the study
G. Prager.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.